Immune predictors of oral poliovirus vaccine immunogenicity among infants in south India
File(s)s41541-020-0178-5.pdf (632.4 KB)
Published version
Author(s)
Grassly, Nicholas
Type
Journal Article
Abstract
Identification of the causes of poor oral vaccine immunogenicity in low-income countries might lead to more effective vaccines. We measured mucosal and systemic immune parameters at the time of vaccination with oral poliovirus vaccine (OPV) in 292 Indian infants aged 6–11 months, including plasma cytokines, leukocyte counts, fecal biomarkers of environmental enteropathy and peripheral blood T-cell phenotype, focused on gut-homing regulatory CD4+ populations. We did not find a distinct immune phenotype associated with OPV immunogenicity, although viral pathogens were more prevalent in stool at the time of immunization among infants who failed to seroconvert (63.9% vs. 45.6%, p = 0.002). Using a machine-learning approach, we could predict seroconversion a priori using immune parameters and infection status with a median 58% accuracy (cross-validation IQR: 50–69%) compared with 50% expected by chance. Better identification of immune predictors of OPV immunogenicity is likely to require sampling of mucosal tissue and improved oral poliovirus infection models.
Date Issued
2020-03-23
Date Acceptance
2020-03-03
Citation
npj Vaccines, 2020, 5, pp.1-8
ISSN
2059-0105
Publisher
Nature Research (part of Springer Nature)
Start Page
1
End Page
8
Journal / Book Title
npj Vaccines
Volume
5
Copyright Statement
© The Author(s) 2020.
This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
Sponsor
Bill & Melinda Gates Foundation
Medical Research Council (MRC)
Identifier
https://www.nature.com/articles/s41541-020-0178-5
Grant Number
OPP1039135
MR/R015600/1
Subjects
Science & Technology
Life Sciences & Biomedicine
Immunology
Medicine, Research & Experimental
Research & Experimental Medicine
HUMAN ROTAVIRUS VACCINE
DEVELOPING-COUNTRIES
GUT MICROBIOTA
CHILDREN
INFECTION
EFFICACY
DIARRHEA
NEWBORN
VIRUS
TRIAL
Live attenuated vaccines
Paediatric research
Publication Status
Published
Article Number
27
Date Publish Online
2020-03-23